Hong Fang Song

Pillar Biosciences, Inc. is a clinical cancer diagnostics company. The firm engages in the creation of precision NGS panels and software solutions. It offers solid tumor panels, blood cancer panels, inherited disease panels, and custom panels. The company was founded by Gang Song and Zhaohui Wang in 2014 and is headquartered in Natick, MA.

Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA

ORI Capital Investment Advisory Hong Kong Ltd (ORI Capital) is a venture capital firm in Hong Kong. The firm was founded by Simone Song in 2015. The firm is headquartered in Hong Kong.

OnCusp Therapeutics is a biotechnology company based in New York, NY and has subsidiaries in China. OnCusp Therapeutics specializes in developing preclinical assets to clinical proof of concept and then partnering out for commercialization in the field of oncology therapeutics. The company is committed to accelerating the advancement of oncology assets by leveraging its deep translational and clinical development expertise. OnCusp Therapeutics is backed by prominent investors including Sequoia Capital, Biotrack Capital, Oriza Seed Capital, and AIHC Capital. The company was founded in 2021 by Andy Fu, Bing Yuan, and Eric Slosberg, with Bing Yuan serving as the CEO since then.

Eyecool Therapeutics, Inc. develops novel device-based technology for the treatment of dry eye. The company is based in Cambridge, MA.

Brixton Biosciences, Inc. has developed coolio™ therapy, an injection that provides long-lasting pain relief as an alternative to opioids. The company is based in Cambridge, MA and was founded by Robert M. Forrester and Sameer A. Sabir. The therapy is designed to desensitize pain in a targeted area and has the potential to eradicate the pain of pain.

IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation.

EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA.

Deciduous Therapeutics, Inc. engages in the biotechnology business. It develops novel therapies to activate the endogenous immune system to treat age related diseases. The company is headquartered in San Francisco, CA.

Part of Medline Industries LP (Illinois), SevenOaks Biosystems LLC is a company that develops medical devices. The company is based in Cambridge, MA. The company was founded by Richard Rox Anderson, Sameer A. Sabir. SevenOaks Biosystems was acquired by Medline Industries LP (Illinois) on November 30, 2016.

Rhapsody Biologics, Inc. develops a personalized peptide vaccine platform. It predicts and optimizes peptide vaccines for use at an individual and population level. Its platform technology encompasses a discovery system to identify immunogenic fragments of disease causing agents that will stimulate an immune response. The company was founded by Richard Paul Kivel and Ren Ee Chee in October 2009 and is headquartered in Norwell, MA.

Atlantic Healthcare Plc operates as holding company with interest in pharmaceutical. Its products include Alicaforsen Enema, an anti-inflammatory intercellular adhesion molecule inhibitor that acts by inhibiting a key protein in the inflammation process. The firm offers its product for the treatment of pouchitis and ulcerative colitis. The company was founded by Toby Wilson Waterworth and Fiona Mary Wilson Waterworth in 2006 and is headquartered in Saffron Walden, the United Kingdom.

FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA.